Gilead Sciences, Inc., 10% Owner at Xilio Therapeutics, Inc. (XLO), bought 3,519,956 shares at $1.04 ($3.7M) on 2024-12-18, disclosed to the SEC on 2024-12-19.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $1.04 | 1,759,978 | $1.8M | 50.0% |
| 2 | $1.04 | 1,759,978 | $1.8M | 50.0% |
| Total | $1.04 avg | 3,519,956 | $3.7M | 100% |
| Filing → |
| XLO | BUY | 2024-04-03 | $369K | — | Filing → |
| KYTX | BUY | 2024-02-13 | $20.0M | — | Filing → |
| RCUS | BUY | 2024-01-31 | $320.0M | — | Filing → |